How Common Is Arthritis in Cats?
Degenerative Joint Disease (DJD) is far more prevalent in cats than previously recognized. According to a study published in the Journal of Feline Medicine and Surgery (Hardie et al., 2002), X-ray examinations reveal that over 90% of cats aged 12 and older have degenerative changes in at least one joint. Even in younger cats, the prevalence is approximately 61% among those over 6 years old (Lascelles et al., 2010). This makes DJD one of the most common yet most easily overlooked sources of chronic pain in cats.
Why Is Feline Arthritis Often Overlooked?
According to the AAFP and ISFM joint statement (2022), feline arthritis is severely underdiagnosed for the following reasons:
- Cats Are Masters at Hiding Pain: As solitary predators, cats instinctively conceal signs of weakness
- Subtle Symptom Presentation: Unlike dogs, which show obvious limping, cats more often exhibit behavioral changes
- Owner Misinterpretation: Decreased activity is often attributed to "getting old" or "personality changes"
- Difficult Clinical Examination: Cats easily become stressed at the clinic, making it difficult to accurately assess joint pain through palpation
- X-ray Findings Don't Always Correlate with Clinical Signs: The severity of radiographic changes does not necessarily reflect the degree of pain
Signs of Arthritis
| Category | Presentation |
|---|---|
| Mobility Changes | Reluctance to jump, hesitation when jumping up or down, difficulty with stairs, reduced range of activity |
| Daily Behavior Changes | Avoiding the litter box (difficulty getting in/out), decreased grooming or excessive licking of painful areas |
| Social Changes | Reduced interaction with people or other animals, increased hiding, increased irritability |
| Posture Changes | Stiff gait, slow to rise, altered resting positions |
| Muscle Atrophy | Decreased muscle mass in affected limbs, especially the hind legs |
Diagnosis
According to AAFP guidelines, DJD diagnosis in cats should incorporate a multi-faceted assessment:
- Owner Questionnaire: Using validated pain assessment tools such as the Feline Musculoskeletal Pain Index (FMPI)
- Orthopedic Examination: Gently evaluating joint range of motion, swelling, and pain responses
- Imaging: X-rays can reveal osteophyte (bone spur) formation and joint space narrowing
- Ruling Out Other Conditions: Hyperthyroidism, diabetic neuropathy, and other conditions can also cause decreased mobility
Pain Management
Pharmaceutical Treatment
In 2023, the U.S. FDA approved Solensia (frunevetmab) — a monoclonal antibody targeting nerve growth factor (NGF), administered as a monthly subcutaneous injection, representing a revolutionary advance in feline DJD pain management. According to its clinical trial (Gruen et al., 2021, Journal of Veterinary Internal Medicine), Solensia was significantly superior to placebo in improving cat mobility and reducing pain.
- Solensia (frunevetmab): Monthly injection with minimal side effects; currently the first-line treatment
- Meloxicam: Long-term low-dose use requires close monitoring of kidney function (ISFM guidelines recommend regular blood tests)
- Gabapentin: Can supplement chronic pain management, especially for neuropathic pain
- Buprenorphine: Used for short-term relief during acute pain episodes
Environmental Modifications
According to AAFP/ISFM recommendations, environmental modifications are an essential component of arthritis management:
- Litter Box: Use a large litter box with low entry sides for easy access
- Steps/Ramps: Place steps or ramps beside sofas, beds, and window sills
- Food Bowl Placement: Raise food and water bowls to an appropriate height to reduce neck bending
- Warm, Soft Resting Areas: Provide heated pads or memory foam beds
- Multi-Level Resource Distribution: Ensure food, water, and litter boxes are available on the same floor
Supplements and Complementary Therapies
| Supplement | Evidence Level | Description |
|---|---|---|
| Omega-3 Fatty Acids (EPA/DHA) | Moderate | Has anti-inflammatory properties; fish oil sources are recommended (Lascelles et al., 2010) |
| Glucosamine/Chondroitin | Limited | Clinical evidence in cats is insufficient, but safety profile is good |
| Green-Lipped Mussel Extract | Limited | Contains Omega-3 and glycosaminoglycans; some studies show benefit |
| Pentosan Polysulfate (Cartrophen) | Moderate | Injectable; can improve joint fluid quality |
According to WSAVA nutrition guidelines, supplements should be considered complementary and cannot replace proper pain management. Weight control is equally important — maintaining an ideal body condition significantly reduces joint stress.
References
- Hardie, E.M. et al. (2002). Radiographic evidence of degenerative joint disease in geriatric cats. Journal of the American Veterinary Medical Association, 220(5), 628-632.
- Lascelles, B.D.X. et al. (2010). DJD-associated pain in cats. Journal of Feline Medicine and Surgery, 12(3), 200-212.
- Gruen, M.E. et al. (2021). A placebo-controlled study of frunevetmab in cats with degenerative joint disease-associated pain. Journal of Veterinary Internal Medicine, 35(6), 2603-2613.
- AAFP/ISFM. (2022). Feline osteoarthritis management guidelines.
- WSAVA. (2020). Global Nutrition Guidelines for Dogs and Cats.